Pentagon Awards Cardinal Health $1.5 Billion Contract
By Adam L. Cataldo
Cardinal Health secured a $1.5 billion government contract as part of the Defense Department's Medical Surgical Prime Vendor program.
The fixed-price, indefinite-delivery/indefinite-quantity contracts were awarded as part of a competitive bidding process, the department said Tuesday. Eight bids were submitted.
The award is a two-year. six-month base contract, and includes three two-year six-month option periods. The ordering period end date is Dec. 6, 2029, the department said.
The contracting activity was handled by the Defense Logistics Agency Troop Support in Philadelphia.
Write to Adam Cataldo at adam.cataldo@wsj.com
(END) Dow Jones Newswires
October 27, 2026 19:17 ET (23:17 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
